Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Abstract Background We evaluated treatment decisions and outcomes in a cohort of predominately Caucasian patients with EGFR mutation-positive (EGFR Mut+) non-small-cell lung cancer (NSCLC). Methods REASON (NCT00997230) was a non-interventional study in German patients with stage IIIB/IV NSCLC. Secon...

Full description

Bibliographic Details
Main Authors: Wolfgang Schuette, Peter Schirmacher, Wilfried E. E. Eberhardt, Manfred Dietel, Ute Zirrgiebel, Lars Muehlenhoff, Michael Thomas
Format: Article
Language:English
Published: BMC 2018-02-01
Series:BMC Cancer
Subjects:
EGFR-mutations
Non-small cell lung cancer (NSCLC)
EGFR tyrosine kinase inhibitor
Observational
REASON study
Online Access:http://link.springer.com/article/10.1186/s12885-018-4032-3

Internet

http://link.springer.com/article/10.1186/s12885-018-4032-3

Similar Items